Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cisplatin or Carboplatin for Advanced Non–Small-Cell Lung Cancer?

Cisplatin or Carboplatin for Advanced Non–Small-Cell Lung Cancer? LETTERS TO THE EDITOR 3. Sandler A, Gray R, Perry MC, et al. Paclitaxel– As we know, good-designed ran- Cisplatin or  carboplatin alone or with bevacizumab for domized clinical trials provide strong non–small-cell lung cancer. New England Carboplatin for  evidence that may change the current Journal of Medicine 2006;355:2542–2550. treatment pattern. Rosell and colleagues 4. Rosell R, Gatzemeier U, Betticher DC, et al. Advanced Non–Small- Phase III randomised trial comparing pacli- conducted direct comparison of pacli- taxel/carboplatin with paclitaxel/cisplatin in taxel/carboplatin versus paclitaxel/cispl- Cell Lung Cancer? patients with advanced non-small-cell lung atin in advanced NSCLC. The baseline cancer: a cooperative multinational trial. Ann patient’s characteristics and follow-up Oncol 2002;13:1539–1549. To the Editor: therapy were well balanced between 5. Ardizzoni A, Boni L, Tiseo M, et al. We have read with great inter- XXX Cisplatin- versus carboplatin-based chemo- the two treatment arms. The overall therapy in first-line treatment of advanced est the article “Cisplatin versus response rate in the two arms of pacli- non-small-cell lung cancer: an individual Carboplatin-Based Regimens for the taxel/carboplatin and paclitaxel/cis- patient data meta-analysis. J Natl Cancer Inst Treatment of Patients with Metastatic platin was 28% and 25%, respectively, 2007;99:847–857. Lung Cancer. An Analysis of Veterans which was similar. However, patients Health Administration Data” reported received paclitaxel/cisplatin had the sig- XXX by Santana-Davila and colleagues in nificantly longer median survival (9.8 Journal of Thoracic oncology (May EGFR Mutations in  months) than paclitaxel/carboplatin (8.2 2014). We are impressed that the months). This is confirmed by an indi- Asian Patients with  authors presented a great retrospec- 5 vidual patient data meta-analysis. In tive study with competent data and Advanced Lung  patients with non-squamous histology, accurate statistical analysis. However, cisplatin-based chemotherapy prolonged Adenocarcinoma selection bias obviously existed in the survival in comparison to carboplatin- study, as they stated in the discussion based chemotherapy (hazard ratio = part. First, although the study sample 1.12, 95% confidence interval = 1.01– To the Editor: is large enough, which included 4352 1.23), but not in squamous histology. In 1 We congratulate Shi et al for patients, only 291 (6.7%) patients in our opinion, there are enough evidences their prospective multinational, epide- the cisplatin group. Second, the inho- to support use of cisplatin in advanced miological study of epidermal growth mogeneity of combined chemothera- NSCLC, especially in non-squamous factor receptor (EGFR) mutations in peutic agents may affect the overall histology. In our daily clinical practice, patients from Asia with newly diag- survival. Approximately 30% of for eligible patients with non-squamous nosed advanced lung adenocarcinoma patients treated with cisplatin were NSCLC, we would like to recommend (PIONEER study) which showed that administered with etoposide, whereas cisplatin preferentially. 51.4% of tumors from 1450 patients only 1.7% of patients in the carbo- had a positive EGFR mutation status. platin group. Third, bevacizumab was Although the frequency of EGFR muta- Xiaoli Sun, MD used more in carboplatin group (5.9%) tions was 50% or higher for patients Department of Radiotherapy than in cisplatin group (0.7%). When of East Asian ethnicities (Vietnamese, added to paclitaxel/carboplatin, it 64.2%; Thai, 53.8%; Chinese, 51.8%, Yulong Zheng, MD can improve survival in previously and Filipino, 50.0%), it was significantly Department of Medical Oncology untreated patients with advanced non- lower for Indian patients (21.9%). Our The First Affiliated Hospital squamous non–small-cell lung cancer study on Malaysian patients who were (NSCLC). In addition, the authors did of Zhejiang University of three major ethnicities, ie, Chinese, not mention the post-study treatment. Hangzhou, China Malay, and Indian, showed that 39.5% During the last decade, many advances of tumors from 812 patients with have been made in the treatment of REFERENCES advanced adenocarcinoma were EGFR advanced NSCLC, e.g., targeted ther- 1. Santana-Davila R, Szabo A, Arce-Lara mutation positive. The frequency of apy. Further treatment after first-line C, Williams CD, Kelley MJ, Whittle J. EGFR mutations was not significantly chemotherapy may also impact on Cisplatin versus carboplatin-based regimens different between our Chinese (40.8% overall survival. for the treatment of patients with meta- of 517 patients), Malay (37.2% of 239 static lung cancer. an analysis of Veterans Health Administration data. J Thorac Oncol 2014;9:702–709. Address for correspondence: Xiaoli Sun, MD, 2. Bonomi P, Kim K, Fairclough D, et al. Address for correspondence: Chong-Kin Liam, Department of Radiotherapy, The First Comparison of survival and quality of life MBBS, MRCP, Department of Medicine, Affiliated Hospital of Zhejiang University, in advanced non–small-cell lung cancer Faculty of Medicine, University of Malaya, 79 Qingchun Road, Hangzhou, Zhejiang, patients treated with two dose levels of pacli- 50603 Kuala Lumpur, Malaysia. E-mail: 310003, China. E-mail: fox006@163.com taxel combined with cisplatin versus eto- liamck@ummc.edu.my Copyright © 2014 by the International Association poside with cisplatin: Results of an Eastern Copyright © 2014 by the International Association for the Study of Lung Cancer Cooperative Oncology Group trial. Journal of for the Study of Lung Cancer ISSN: 1556-0864/14/0909-0e70 ISSN: 1556-0864/14/0909-0e70 Clinical Oncology 2000;18:623–623. Journal of Thoracic Oncology  • Volume 9, Number 9, September 2014 e70 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Cisplatin or Carboplatin for Advanced Non–Small-Cell Lung Cancer?

Journal of Thoracic Oncology , Volume 9 (9) – Sep 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/cisplatin-or-carboplatin-for-advanced-non-ndash-small-cell-lung-cancer-Yh0Rd0pNQz

References (11)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000246
pmid
25122440
Publisher site
See Article on Publisher Site

Abstract

LETTERS TO THE EDITOR 3. Sandler A, Gray R, Perry MC, et al. Paclitaxel– As we know, good-designed ran- Cisplatin or  carboplatin alone or with bevacizumab for domized clinical trials provide strong non–small-cell lung cancer. New England Carboplatin for  evidence that may change the current Journal of Medicine 2006;355:2542–2550. treatment pattern. Rosell and colleagues 4. Rosell R, Gatzemeier U, Betticher DC, et al. Advanced Non–Small- Phase III randomised trial comparing pacli- conducted direct comparison of pacli- taxel/carboplatin with paclitaxel/cisplatin in taxel/carboplatin versus paclitaxel/cispl- Cell Lung Cancer? patients with advanced non-small-cell lung atin in advanced NSCLC. The baseline cancer: a cooperative multinational trial. Ann patient’s characteristics and follow-up Oncol 2002;13:1539–1549. To the Editor: therapy were well balanced between 5. Ardizzoni A, Boni L, Tiseo M, et al. We have read with great inter- XXX Cisplatin- versus carboplatin-based chemo- the two treatment arms. The overall therapy in first-line treatment of advanced est the article “Cisplatin versus response rate in the two arms of pacli- non-small-cell lung cancer: an individual Carboplatin-Based Regimens for the taxel/carboplatin and paclitaxel/cis- patient data meta-analysis. J Natl Cancer Inst Treatment of Patients with Metastatic platin was 28% and 25%, respectively, 2007;99:847–857. Lung Cancer. An Analysis of Veterans which was similar. However, patients Health Administration Data” reported received paclitaxel/cisplatin had the sig- XXX by Santana-Davila and colleagues in nificantly longer median survival (9.8 Journal of Thoracic oncology (May EGFR Mutations in  months) than paclitaxel/carboplatin (8.2 2014). We are impressed that the months). This is confirmed by an indi- Asian Patients with  authors presented a great retrospec- 5 vidual patient data meta-analysis. In tive study with competent data and Advanced Lung  patients with non-squamous histology, accurate statistical analysis. However, cisplatin-based chemotherapy prolonged Adenocarcinoma selection bias obviously existed in the survival in comparison to carboplatin- study, as they stated in the discussion based chemotherapy (hazard ratio = part. First, although the study sample 1.12, 95% confidence interval = 1.01– To the Editor: is large enough, which included 4352 1.23), but not in squamous histology. In 1 We congratulate Shi et al for patients, only 291 (6.7%) patients in our opinion, there are enough evidences their prospective multinational, epide- the cisplatin group. Second, the inho- to support use of cisplatin in advanced miological study of epidermal growth mogeneity of combined chemothera- NSCLC, especially in non-squamous factor receptor (EGFR) mutations in peutic agents may affect the overall histology. In our daily clinical practice, patients from Asia with newly diag- survival. Approximately 30% of for eligible patients with non-squamous nosed advanced lung adenocarcinoma patients treated with cisplatin were NSCLC, we would like to recommend (PIONEER study) which showed that administered with etoposide, whereas cisplatin preferentially. 51.4% of tumors from 1450 patients only 1.7% of patients in the carbo- had a positive EGFR mutation status. platin group. Third, bevacizumab was Although the frequency of EGFR muta- Xiaoli Sun, MD used more in carboplatin group (5.9%) tions was 50% or higher for patients Department of Radiotherapy than in cisplatin group (0.7%). When of East Asian ethnicities (Vietnamese, added to paclitaxel/carboplatin, it 64.2%; Thai, 53.8%; Chinese, 51.8%, Yulong Zheng, MD can improve survival in previously and Filipino, 50.0%), it was significantly Department of Medical Oncology untreated patients with advanced non- lower for Indian patients (21.9%). Our The First Affiliated Hospital squamous non–small-cell lung cancer study on Malaysian patients who were (NSCLC). In addition, the authors did of Zhejiang University of three major ethnicities, ie, Chinese, not mention the post-study treatment. Hangzhou, China Malay, and Indian, showed that 39.5% During the last decade, many advances of tumors from 812 patients with have been made in the treatment of REFERENCES advanced adenocarcinoma were EGFR advanced NSCLC, e.g., targeted ther- 1. Santana-Davila R, Szabo A, Arce-Lara mutation positive. The frequency of apy. Further treatment after first-line C, Williams CD, Kelley MJ, Whittle J. EGFR mutations was not significantly chemotherapy may also impact on Cisplatin versus carboplatin-based regimens different between our Chinese (40.8% overall survival. for the treatment of patients with meta- of 517 patients), Malay (37.2% of 239 static lung cancer. an analysis of Veterans Health Administration data. J Thorac Oncol 2014;9:702–709. Address for correspondence: Xiaoli Sun, MD, 2. Bonomi P, Kim K, Fairclough D, et al. Address for correspondence: Chong-Kin Liam, Department of Radiotherapy, The First Comparison of survival and quality of life MBBS, MRCP, Department of Medicine, Affiliated Hospital of Zhejiang University, in advanced non–small-cell lung cancer Faculty of Medicine, University of Malaya, 79 Qingchun Road, Hangzhou, Zhejiang, patients treated with two dose levels of pacli- 50603 Kuala Lumpur, Malaysia. E-mail: 310003, China. E-mail: fox006@163.com taxel combined with cisplatin versus eto- liamck@ummc.edu.my Copyright © 2014 by the International Association poside with cisplatin: Results of an Eastern Copyright © 2014 by the International Association for the Study of Lung Cancer Cooperative Oncology Group trial. Journal of for the Study of Lung Cancer ISSN: 1556-0864/14/0909-0e70 ISSN: 1556-0864/14/0909-0e70 Clinical Oncology 2000;18:623–623. Journal of Thoracic Oncology  • Volume 9, Number 9, September 2014 e70

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2014

There are no references for this article.